# Xoc Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/xoc-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Los Gatos, US
- Website: www.xocpharma.com
- Total disclosed funding: $11M
- Latest round: Series A (Jan 12, 2018)
- Investors on record: 1

## About

Xoc Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative pharmaceutical solutions to address unmet medical needs with advanced therapeutic technologies.Founded in 2013 and headquartered in Los Gatos, California, Xoc Pharmaceuticals, Inc. specializes in the development of pharmaceutical products. The company has pivoted its strategy to focus on advanced therapeutic technologies and secured a USD 10.98 mn Series A funding round led by New Enterprise Associates in January 2018, raising a total of USD 10.98 mn to date. The firm has engaged in one deal to date, with a current company valuation of USD 43.908 mn. Scott Borland serves as the CEO.Xoc Pharmaceuticals, Inc. specializes in providing innovative technology solutions aimed at enhancing operational efficiency across the pharmaceutical sector. Its core product offerings include a suite of advanced pharmaceuticals designed for specific therapeutic areas, aimed at improving patient outcomes. These products are rolled out in key markets, including North America and Europe, and are expanding into the Asia-Pacific region.The company operates on a subscription-based revenue model, allowing healthcare providers to access its pharmaceutical solutions through tailored pricing plans. Revenue generation mechanisms include annual and monthly subscriptions, providing flexibility across various customer segments. Clients typically engage in direct agreements to procure product licenses, often bundled with premium support services. The firm maintains strong client relationships, enhancing retention through ongoing product updates and enhancements.Xoc Pharmaceuticals, Inc. plans to leverage its recent USD 10.98 mn Series A funding to accelerate the development of new therapeutic products aimed at addressing specific medical conditions. The company will target expansion into the Asia-Pacific market by 2025, aiming to increase its global footprint and customer base. Recent funding will be utilized to support research and development efforts, ensuring timely product launches that align with market needs.

## Funding rounds

- Series A, Jan 12, 2018, $11M — New Enterprise Associates

## Investors

- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A